Testing vorasidenib with temozolomide after radiation for advanced brain cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with grade 3 astrocytoma with an IDH mutation (a specific gene change).
- Your tumor does not have a loss of both copies of the CDKN2A/B genes or a 1p/19q co-deletion.
- You have not had any prior chemotherapy, radiation, or targeted therapy for your brain tumor.
- You are at least 12 years old and able to undergo an MRI.
- You have adequate organ function (kidney, liver, blood counts) and are generally healthy enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy called safusidenib for people whose brain tumor (glioma) has an IDH1 mutation and who have already taken vorasidenib but the tumor kept growing. The study aims to see if safusidenib can help when vorasidenib stops working.
This trial studies an oral drug called vorasidenib for children and teens with a slow-growing brain tumor (Grade 2 astrocytoma or oligodendroglioma) that has an IDH1 or IDH2 mutation. The drug is taken daily and may help keep the tumor from growing, avoiding the need for immediate chemotherapy or radiation.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
This trial tests a combination of two oral medications (vorasidenib and lomustine) for people whose brain tumor (glioma) has come back and has an IDH1 or IDH2 mutation. The goal is to see if this combination is safe and effective in halting or slowing tumor growth.
This trial tests giving a chemotherapy drug called temozolomide before radiation therapy to people with a newly diagnosed high-grade brain tumor. The goal is to see if this approach can help control the tumor better.
Hear when a new Astrocytoma, IDH-Mutant, Grade 3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.